Eutilex Co Ltd
263050
Company Profile
Business description
Eutilex Co Ltd is a Korean that operates in the anti-tumor immunotherapy market. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, and Antibody.
Contact
Daeryung Technotown 17
Suite 1401
Gasan Digital 1-ro 25
Geumcheon-gu
Seoul08594
KORT: +82 234027310
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
141
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,175.10 | 49.90 | 0.61% |
| CAC 40 | 7,536.26 | 33.48 | 0.45% |
| DAX 40 | 22,242.45 | 177.94 | 0.81% |
| Dow JONES (US) | 40,113.50 | 20.10 | 0.05% |
| FTSE 100 | 8,415.25 | 7.81 | 0.09% |
| HKSE | 21,980.74 | 70.98 | 0.32% |
| NASDAQ | 17,382.94 | 216.90 | 1.26% |
| Nikkei 225 | 35,705.74 | 666.59 | 1.90% |
| NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
| S&P 500 | 5,525.21 | 40.44 | 0.74% |
| S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
| SSE Composite Index | 3,295.06 | 2.23 | -0.07% |